KZR Files 8-K; Exhibit 99.1 Press Release Announces Q2 2025 Results

Rhea-AI Filing Summary

Kezar Life Sciences reported it issued a press release announcing its financial results for the fiscal quarter ended June 30, 2025. The current report furnishes that press release as Exhibit 99.1 and incorporates it by reference. The filing also includes a Cover Page Interactive Data File as Exhibit 104.

The company states that the information furnished under Item 2.02, including Exhibit 99.1, is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings except as expressly stated. No additional financial detail or analysis is included within this report.

Insights

Securities Analyst

TL;DR: This 8-K furnishes a press release announcing Q2 2025 results but does not provide the underlying financial figures in the filing itself.

The filing explicitly furnishes a press release as Exhibit 99.1 that announces the company's financial results for the quarter ended June 30, 2025, and includes an Inline XBRL cover page as Exhibit 104. The company states the press release is "furnished" and not "filed" under Section 18, limiting statutory liability for this report. Because the 8-K does not include the substantive financial tables or metrics within its text, investors must consult Exhibit 99.1 to review the actual results. Impact assessment: not impactful—the report signals a disclosure but does not by itself change financial transparency.

Corporate Governance Expert

TL;DR: The report follows standard disclosure practice by furnishing a results press release and clarifying its "furnished" status under the Exchange Act.

The document formally furnishes the press release reporting quarterly results and attaches the Inline XBRL cover page. The explicit disclaimer that the furnished material is not "filed" under Section 18 is a routine legal distinction clarifying liability and incorporation by reference. From a governance and disclosure control perspective, the 8-K documents the communication but does not itself provide new operational or financial metrics. Impact assessment: not impactful—procedural disclosure without material new data in the filing.

false000164566600016456662025-08-132025-08-130001645666us-gaap:CommonStockMember2025-08-132025-08-130001645666us-gaap:RightsMember2025-08-132025-08-13

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

__________________________________________________________

FORM 8-K

__________________________________________________________

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 13, 2025

__________________________________________________________

Kezar Life Sciences, Inc.

(Exact name of Registrant as Specified in Its Charter)

__________________________________________________________

Delaware			001-38542			47-3366145
(State or Other Jurisdiction of Incorporation)			(Commission File Number)			(IRS Employer Identification No.)
4000 Shoreline Court, Suite 300 South San Francisco, California						94080
(Address of Principal Executive Offices)						(Zip Code)

Registrant’s Telephone Number, Including Area Code: 650 822-5600

(Former Name or Former Address, if Changed Since Last Report)

__________________________________________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading symbol

Name of each exchange on which registered

Common Stock, $0.001 par value

KZR

The Nasdaq Stock Market LLC

Preferred Share Purchase Rights

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Item 2.02 Results of Operations and Financial Condition.

On August 13, 2025, Kezar Life Sciences, Inc. (the “Company”) issued a press release announcing its financial results for the fiscal quarter ended June 30, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information provided under this Item 2.02 in this Form 8-K, including Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any of the Company’s filings under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.						Description
99.1						Press release of the Company, dated August 13, 2025
104						Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

									KEZAR LIFE SCIENCES, INC.
Date:			August 13, 2025			By:			/s/ Marc L. Belsky
									Marc L. Belsky Chief Financial Officer and Secretary

FAQ

What did Kezar Life Sciences (KZR) disclose in this 8-K?

The company furnished a press release announcing financial results for the fiscal quarter ended June 30, 2025 and listed it as Exhibit 99.1; Exhibit 104 (Inline XBRL cover page) is also included.

Is the press release in the 8-K considered "filed" with the SEC?

No. The filing explicitly states the press release and related information are "furnished" and are not deemed "filed" for purposes of Section 18 of the Exchange Act.

Where can I find the actual financial figures referred to in this 8-K?

The 8-K furnishes the press release as Exhibit 99.1. The press release (Exhibit 99.1) is the document that announces the financial results; consult that exhibit to view the figures.

Does this 8-K include financial statements or detailed tables?

No detailed financial statements or tables are included in the body of this report. The filing lists only Exhibit 99.1 (press release) and Exhibit 104 (cover page interactive data file).

Does the filing state whether Kezar is an emerging growth company?

The filing includes the emerging growth company checkbox section, but it does not state a clear selection within the text provided.